采用液相色谱-串联质谱法测定育龄期1型糖尿病女性的部分雄激素
横断面研究纳入87例1型糖尿病、97例非糖尿病多囊卵巢综合征(PCOS)及101例非糖尿病无PCOS的育龄期女性,用液相色谱-串联质谱法(LC-MS/MS)测定雄激素。1型糖尿病女性中雄烯二酮是区分临床高雄激素表现(HA)和PCOS亚组最有用的指标;1型糖尿病合并PCOS者占18%,较无PCOS者更瘦、初潮更晚、PCOS家族史更常见。
要点
- 1型糖尿病女性中,雄烯二酮是区分临床高雄激素表现和PCOS的敏感生化指标。
- 1型糖尿病合并PCOS者占18%,较无PCOS者更年轻、BMI更低、初潮更晚、PCOS家族史更常见。
- 1型糖尿病合并PCOS者的雄激素水平与BMI匹配的非糖尿病PCOS女性无差异,但雄烯二酮高于肥胖PCOS女性。
核心结论
- 雄烯二酮是1型糖尿病女性临床高雄激素表现和PCOS的敏感生化标志物。
- 1型糖尿病合并PCOS的女性较无PCOS者更瘦,但PCOS家族史更常见。
- 1型糖尿病合并PCOS女性的生化表型与瘦型非糖尿病PCOS女性相似,但与肥胖PCOS女性不同。
- 1型糖尿病中PCOS的机制及其临床意义需进一步研究。
研究设计与样本
- 横断面研究,招募三组育龄期女性:1型糖尿病女性(n=87)、非糖尿病PCOS女性(N=97)和非糖尿病无PCOS女性(N=101)。
- 采用液相色谱-串联质谱法(LC-MS/MS)测定雄激素谱并评估PCOS状态。
主要发现
- 与无糖尿病女性相比,1型糖尿病女性的脱氢表雄酮/硫酸脱氢表雄酮(DHEA/DHEAS)比值更低(P < 0.05)。
- 1型糖尿病女性中,有临床高雄激素表现和排卵障碍者的睾酮水平高于无临床高雄激素表现且月经规律者;有高雄激素表现和排卵障碍者的雄烯二酮水平高于有高雄激素表现且月经规律者以及无高雄激素表现且月经规律者(所有P < 0.05)。
- 1型糖尿病女性中18%合并PCOS,与无PCOS的1型糖尿病女性相比,合并PCOS者更年轻、BMI更低、初潮年龄更晚、PCOS家族史阳性率更高(所有P < 0.05)。
- 1型糖尿病合并PCOS女性的雄激素水平与BMI匹配的非糖尿病PCOS女性无差异,但雄烯二酮水平高于肥胖PCOS女性(P < 0.05)。
局限性
- 研究的患者亚组相对较小,降低了检测微小差异的把握度。
- 未采用平衡透析法测定游离睾酮水平,也未计算游离睾酮——常用计算公式尚未在1型糖尿病中得到验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What information does androgen profiling using liquid chromatography tandem mass spectrometry (LC-MS/MS) provide in reproductive-age women with Type 1 diabetes (T1D)? SUMMARY ANSWER: In T1D women, androstenedione proved most useful of the measured androgens in differentiating subgroups based on clinical phenotypes of hyperandrogenism (HA) and polycystic ovary syndrome (PCOS). WHAT IS KNOWN ALREADY: The prevalence of HA and PCOS are increased in women with T1D. These observations are based on measurement of serum androgens using immunoassays, to-date no studies using LC-MS/MS have been reported in reproductive-age women with T1D. STUDY DESIGN, SIZE, DURATION: This was a cross-sectional study with recruitment of three groups of reproductive-age women: women with T1D (n = 87), non-diabetic women with (N = 97) and without PCOS (N = 101). PARTICIPANTS/MATERIALS, SETTING, METHODS: Using LC-MS/MS, we aimed to characterize androgen profiles and PCOS status in women with T1D, and interpret findings in relation to cohorts of non-diabetic women with and without PCOS. MAIN RESULTS AND THE ROLE OF CHANCE: Compared to non-diabetic women, dehydroepiandrosterone/dehydroepiandrosterone sulphate (DHEA/DHEAS) ratio was lower (P < 0.05) in women with T1D. Testosterone levels were greater in T1D women with clinical HA and anovulation compared to those without clinical HA and with regular cycles, while androstenedione levels were greater in T1D women with HA and anovulation compared to those with HA and regular cycles and also those without HA and with regular cycles (P < 0.05 for all). Compared to T1D women without PCOS, the 18% of T1D women who had PCOS were younger with lower BMI, an older age of menarche, and were more likely to have a positive family history of PCOS (P < 0.05 for all). Androgen levels did not differ between women with T1D and PCOS compared to BMI-matched non-diabetic women with PCOS, but androstenedione levels were greater in T1D women with PCOS compared to obese women with PCOS (P < 0.05). LIMITATIONS, REASONS FOR CAUTION: Relatively small subgroups of patients were studied, reducing the power to detect small differences. Free testosterone levels were not measured using equilibrium dialysis, and were not calculated - commonly used formulae have not been validated in T1D. WIDER IMPLICATIONS OF THE FINDINGS: Androstenedione is a sensitive biochemical marker of clinical hyperandrogenism and PCOS in T1D. T1D women with PCOS are leaner than those without PCOS but are more likely to have a family history of PCOS. Women with T1D and PCOS have a similar biochemical phenotype to lean non-diabetic women with PCOS but differ from obese women with PCOS. The mechanisms underlying PCOS in T1D and its clinical significance require further investigation. STUDY FUNDING/COMPETING INTEREST(S): The study was part-funded by the Meath Foundation. The authors have no competing interests.
引用
- Gunness A, Pazderska A, Ahmed M, et al. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes. Hum Reprod. 2018. PMID: 30020477. doi:10.1093/humrep/dey243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。